Live updates from AMCP Annual Meeting

ensitrelvir - Infectious disease Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision oxylanthanum carbonate (Renazorb) Unicycive Hyperphosphatemia (in...

Event on Sept. 11 in Washington D.C. will feature the latest information on using GLP-1s to tackle the obesity epidemic.

Table view Editor-in-chief's message Year 2024 2025 2026 2027 2028 Projected Yearly U.S. Sales $0 $82 $177 $258 $311 The pipeline drug list is an aerial outline of drugs with anticipated FDA...

Name Manufacturer Clinical use Dosage form Development status - FDA designations FDA decision aflibercept (Eylea HD) 8 mg Regeneron Macular edema from RVO (8 mg dose) Intravitreal sNDA – PR Oct-Dec...

Jessica Johnson, clinical consultant, shares how the Special Investigations Unit at Prime helps identify cases of fraud

Real-world, integrated data follows-up on previous insights, analytics.

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

As demand for GLP-1a drugs for weight loss has increased, new data provides additional insights about this new class of medications.

The event emphasizes additional measures for obesity therapy.

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

Submitted supplemental drugs Phase 3 supplemental drugs arimoclomol oral Name Manufacturer Clinical Use Dosage Form Development Status camrelizumab Jiangsu Hengrui HCC (unresectable, 1st-line, in...

Drug Generic Name Therapeutic category July2024 Pipeline - Total US sales for 2028 (Dollars in millions) botaretigene sparoparvovec Ophthalmology / Gene therapy $158 crinecerfont Endocrine $325...

What to expect at Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Forbes

Name Manufacturer Clinical Use Dosage Form Development Status FDA Decision adalimumab-bwwd 40 mg/0.4 mL (Hadlima™) (biosimilar to Abbvie’s Humira®) Organon RA; AS; PSO; PsA; JIA; CD; UC; HS;...

The American Journal of Managed Care (AJMC): The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still...

Managed Healthcare Executive: Use of GLP-1 drugs and weight-loss care management programs need to focus on adherence and persistency for better health outcomes, suggests Prime...

Pharmacy Practice News, originally published by Specialty Pharmacy Continuum

BioSpace: As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health outcomes—evidenced by successful studies in therapeutic areas like...

Manufacturer: Ferring / Seikagaku Proposed indications Radicular leg pain associated with lumbar disc herniation (LDH) Clinical overview Mechanism of action Condoliase, also known as chondroitin...

Editor's message Editorial team Cell therapy= Transplantation of healthy cells to replace or repair damaged ones *Orphan drug status PDUFA= Prescription Drug User Fee Act IV= intravenous...

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

Manufacturer: Abeona Proposed indications Recessive dystrophic epidermolysis bullosa (RDEB) Clinical overview Mechanism of action Prademagene zamikeracel (pz-cel) is an autologous, collagen type...

Cover image for Quarterly Drug Pipeline: January 2025 Updates on promising therapies in development, focusing on drugs nearing FDA approval Prime Therapeutics /quarterly-drug-pipeline-january-2025...

Prime to present seven studies and receive the 2024 JMCP Award for Excellence

cover image for Quarterly Drug Pipeline: October 2024 Quarterly Drug Pipeline: October 2024 Prime Therapeutics /quarterly-drug-pipeline-october-2024 Prime Therapeutics’ Quarterly Drug Pipeline...

Prime Therapeutics researchers share more about award-winning real-world research

Cover image for Quarterly Drug Pipeline: April 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-april-2025 Prime...

Cover image for Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2025 Prime...

Cover image for Quarterly Drug Pipeline: October 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-october-2025...

cover image for Quarterly Drug Pipeline: January 2026 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-january-2026...

Specialty Pharmacy Continuum

Managed Healthcare Executive

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

Academy of Managed Care Pharmacy (AMCP)

BioPharma Dive: There are no drugs specifically for polycystic ovary syndrome, a chronic condition that can cause infertility. One study is testing whether Wegovy might be beneficial.

Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care